Back

Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in diabetic patients with a higher impact on women

4 April 2025 (11:06 - 11:15)
Organised by: Logo
Congress Presentation Part of: Protecting the female heart life-long Cardiovascular Disease in Women EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

3 More presentations in this session

Presentation thumbnail
Gender differences in prevalence and management of hypertension in Switzerland from 1997 to 2022
Doctor S. Yi (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Evaluation of the age-related prevalence of cardiovascular risk factors to guide systematic long-term follow-up after preeclampsia
Mrs G. Jansen (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Earlier menopause is related to adverse left ventricular morphology and function in the UK Biobank
Doctor J. Marino (Greifswald, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Protecting the female heart life-long

The Event

Event poster

ESC Preventive Cardiology 2025

4 April 2025 11:06 CET
You may be interested in
thumbnail
Congress Presentation
Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women
thumbnail
Congress Presentation
Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
thumbnail
Congress Presentation
Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources